Senior Managing Associate

Longbo Wang

Technology and Life Sciences Transactions

longbo.wang@sidley.com

San Francisco +1 415 772 1241

- Letter
- A4

LONGBO WANG represents clients in the life sciences, technology, media, and entertainment industries on complex intellectual property, technology, and commercial transactions.

In the life sciences sector, Longbo represents biotechnology, pharmaceuticals, and medical devices companies in structuring and negotiating complex transactions, including strategic collaborations, joint ventures, license agreements, asset purchase and sale transactions, and other commercial transactions.

In the technology, media, and entertainment sector, Longbo represents software, Internet, mobile, video game, eSports, and multimedia companies on a wide array of matters ranging from technology development, licensing and procurement agreements, outsourcing and services agreements, and mergers and acquisitions, to the acquisition, development, production, marketing, distribution, and publishing of various media and entertainment content.

Longbo has been named as one of the “Top Ten Outstanding Young Lawyers 2023” by China Legal Education and Career Seminar Series (CLECSS).

Prior to joining Sidley, Longbo was a senior legal counsel and a senior business development manager in Tencent Holdings Limited. Longbo also has experience working at other international law firms in their Shanghai, Hong Kong, and Palo Alto offices.

Experience

Represented Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, in its multi-year, multi-target strategic collaboration agreement with Seagen Inc. (Nasdaq: SGEN) to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer treatment. Under the terms of the agreement, Nurix will receive an upfront payment of US$60 million and the potential to receive up to approximately US$3.4 billion in research, development, regulatory, and commercial milestone payments across multiple programs.
Represented Keymed Biosciences, a China-based, publicly traded (HKEX: 2162) biopharmaceutical company in the out-licensing of CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC) to AstraZeneca (NASDAQ: AZN). Under the terms of the agreement, KYM Biosciences, the joint venture established by Keymed and Lepu Biopharma, will receive an upfront payment of US$63 million on transaction closing and additional development and sales-related milestone payments of up to US$1.1 billion, as well as tiered royalties of up to low double-digits.
Represented ImaginAb, Inc., a California-based biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), on an exclusive license with Yantai DongCheng Pharmaceutical Group to commercialize ImaginAb’s CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) in the Greater China market.
Represented Akeso Inc. in a collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan. Under the terms of the agreement, Akeso will receive a US$500 million upfront payment, with a total potential deal value of up to US$5 billion. Akeso will also receive a low double-digit percentage of royalties on net product sales of ivonescimab.
Represented Myovant Sciences (NYSE: MYOV), a biopharmaceutical company focused on developing innovative treatments for women’s health and prostate cancer, in an exclusive license agreement with Accord Healthcare, Ltd., to commercialize relugolix for the treatment of advanced, hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.
Represented Pivotal bioVenture Partners China, a leading venture capital fund in the field of life sciences, and Frazier Healthcare Partners, a leading provider of growth and venture capital to healthcare companies, in the formation of SanReno Therapeutics, a joint venture with Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, and the equity investment in SanReno.
Represented Vivo Capital and AdvanTech Capital as lead investors in the US$75 million Series A financing for Ablaze Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets.
Represented I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, in its strategic collaboration agreement with Jumpcan Pharmaceutical Group for the development, manufacturing, and commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa (TJ101) in mainland China.
Represented NeuroFront in its exclusive licensing agreement with Neurolief to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and depression, in Greater China and South Korea.
Represented Alebund Pharmaceuticals (Hong Kong) Limited in its option and license agreement with Chugai in relation to its EOS789, an investigational agent under development for hyperphosphatemia.
Represented ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, on an exclusive license agreement with 3D Medicines, Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development, manufacture and commercialization of ImmuneOncia’s monoclonal antibody (IMC-002) in Greater China.
Represented Plexxikon, Inc., a California-based drug discovery company that is a member of Daiichi Sankyo Group, in the following transactions:

A license agreement with cancer biotech company Novellus to research, develop, manufacture and (should it gain approval) exclusively sell worldwide the early clinical-stage BRAF-inhibiting compound PLX8394 for the treatment of solid tumors known as PLX8394. Under the terms of the agreement, Plexxikon received an undisclosed upfront payment, additional developmental milestones and royalty payments in exchange for the rights to PLX8394.
A license agreement with Kiq LLC for worldwide rights to develop and commercialize PLX9486. Under the terms of the agreement, Plexxikon received an upfront payment, and is eligible for additional developmental milestones and mid- to high- single-digit royalty payments. PLX9486 will be studied as a monotherapy in patients with Advanced Systemic Mastocytosis (ASM) and Indolent Systemic Mastocytosis (ISM).

Represented Jiangsu Hengrui Medicine Co., Ltd., a leading biopharmaceutical company in China, in entering into a license agreement with CrystalGenomics, Inc., a South Korea-based biopharmaceutical company, for the exclusive license to CrystalGenomics for the development, regulatory approval and commercialization of Camrelizumab, a PD-1 monoclonal antibody, in South Korea. Hengrui will be entitled to receive a total of up to US$87.75 million in upfront and milestone payments as well as royalties based on the net sales of the licensed product by CrystalGenomics.
Represented Yuhan Corporation, a leading pharmaceutical company in South Korea, in its license agreement with Processa Pharmaceuticals, Inc., for the global (ex-South Korea) rights to develop, manufacture, and commercialize YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).
Advised Tencent Holdings Limited (as in-house counsel) on its collaboration agreements with Nintendo Co., Ltd. to bring the Nintendo Switch video game platform into China, and to publish Nintendo’s video game software for the Nintendo Switch in China.
Advised Tencent Holdings Limited (as in-house counsel) on its joint venture and licensing arrangements with Roblox Corporation. to publish and operate the Roblox platform in China.

Longbo Wang

Credentials

Admissions & Certifications

Education

Languages

Contact